Research Article| Volume 96, ISSUE 4, SUPPLEMENT , 60-66, August 22, 2005

Download started.


Pharmacologic Options for Aggressive Low-Density Lipoprotein Cholesterol Lowering: Benefits Versus Risks

      Lessons from recent end point trials of lipid-lowering drugs indicate that patients at very high risk for coronary artery disease (CAD) benefit from treatment that lowers low-density lipoprotein (LDL) cholesterol plasma levels to ≤1.81 mmol/L (≤70 mg/dL), that patients with ≥2 risk factors benefit from treatment that lowers plasma LDL cholesterol to <2.59 mmol/L (<100 mg/dL), and that a significant reduction in CAD event rates is most often associated with a minimum plasma LDL cholesterol reduction of 30%. Recently, the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) recommendations were amended to incorporate these lessons. To reach these more aggressive goals and plasma LDL cholesterol reductions, more aggressive therapies will be required. The best way to implement more aggressive therapy is to start with one of the more potent statins, especially atorvastatin or rosuvastatin, or higher doses of other statins. This approach alone is likely to achieve treatment goals in 50% to 80% of patients. For patients needing additional plasma LDL cholesterol lowering, combination therapies will be required. Adding colesevelam, ezetimibe, or niacin to a stable statin regimen will generally provide an additional 10% to 15% lowering of plasma LDL cholesterol. These more potent statins, even when used in higher doses, appear to be safe. The incidence of myopathy and rhabdomyolysis, as documented in long-term clinical trials, is <0.1% and <0.01%, respectively, except for simvastatin, which has a higher incidence of these problems. Less information is available about the safety of lowering levels of plasma LDL cholesterol to ≤1.81 mmol/L (≤70 mg/dL), but an analysis of a recent 2-year-long clinical trial, in which patients had on-treatment plasma LDL cholesterol levels as low as 0.67 mmol/L (26 mg/dL), reported no signals of untoward effects in patients with progressively lower levels.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Lipid Research Clinics program
        The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease.
        JAMA. 1984; 251: 351-364
        • Shepherd J.
        • Cobbe S.M.
        • Ford I.
        • Isles C.G.
        • Lorimer A.R.
        • MacFarlane P.W.
        • McKillop J.H.
        • Packard C.J.
        • West of Scotland Coronary Prevention Study Group
        Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.
        N Engl J Med. 1995; 333: 1301-1307
        • Downs J.R.
        • Clearfield M.
        • Whitney E.
        • Shapiro D.
        • Beere P.A.
        • Gotto A.M.
        • Air Force/Texas Coronary Atherosclerosis Prevention Study
        Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels.
        JAMA. 1998; 279: 1615-1622
        • ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group
        Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care.
        JAMA. 2002; 288: 2998-3007
        • Sever P.S.
        • Dahlof B.
        • Poulter N.R.
        • Wedel H.
        • Beevers G.
        • Caulfield M.
        • Collins R.
        • Kjeldsen S.E.
        • Kristinsson A.
        • McInnes G.T.
        • et al.
        • ASCOT investigators
        Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA).
        Lancet. 2003; 361: 1149-1158
        • Scandinavian Simvastatin Survival Study Group
        Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease.
        Lancet. 1994; 344: 1383-1389
        • Buchwald H.
        • Campos C.T.
        • Boen J.R.
        • Nguyen P.A.
        • Williams S.E.
        Disease-free intervals after partial ileal bypass in patients with coronary heart disease and hypercholesterolemia.
        J Am Coll Cardiol. 1995; 26: 351-357
        • Athyros V.G.
        • Papageorgiou A.A.
        • Mercouris B.R.
        • Athyrou V.V.
        • Symeonidis A.N.
        • Basayannis E.O.
        • Demitriadis D.S.
        • Kontopoulos A.G.
        Treatment with atorvastatin to the National Cholesterol Education Program goal versus ‘usual’ care in secondary coronary heart disease prevention.
        Curr Med Res Opin. 2002; 18: 220-228
        • The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
        Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
        N Engl J Med. 1998; 339: 1349-1357
        • Shepherd J.
        • Blauw G.J.
        • Murphy M.B.
        • Bollen E.L.
        • Buckley B.M.
        • Cobbe S.M.
        • Ford I.
        • Gaw A.
        • Hyland M.
        • Jukema J.W.
        • et al.
        • PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) study group
        Pravastatin in elderly individuals at risk of vascular disease (PROSPER).
        Lancet. 2002; 360: 1623-1630
        • Sacks F.M.
        • Pfeffer M.A.
        • Moye L.A.
        • Rouleau J.L.
        • Rutherford J.D.
        • Cole T.G.
        • Brown L.
        • Warnica J.W.
        • Arnold J.M.
        • Wun C.C.
        • et al.
        • Cholesterol and Recurrent Events Trial investigators
        The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.
        N Engl J Med. 1996; 335: 1001-1009
        • Heart Protection Study Collaborative Group
        MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals.
        Lancet. 2002; 360: 7-22
        • Schwartz G.G.
        • Olsson A.G.
        • Ganz E.P.
        • Oliver M.F.
        • Waters D.
        • Zeiher A.
        • Chaitman B.R.
        • Leslie S.
        • Stern T.
        • Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators
        Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes, the MIRACL Study.
        JAMA. 2001; 285: 1711-1718
        • Cannon C.P.
        • Braunwald E.
        • McCabe C.H.
        • Rader D.J.
        • Rouleau J.L.
        • Belder R.
        • Joyal S.V.
        • Hill K.A.
        • Pfeffer M.A.
        • Skene A.M.
        • Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators
        Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes.
        N Engl J Med. 2004; 350: 1495-1504
        • deLemos J.A.
        • Blazine M.A.
        • Wiviott S.D.
        • Lewis E.F.
        • Foz K.A.A.
        • White H.D.
        • Rouleau J.L.
        • Pedersen T.R.
        • Gardner L.H.
        • Mukherjee R.
        • et al.
        • A to Z Investigators
        Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes.
        JAMA. 2004; 292: 1307-1316
        • Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
        Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).
        JAMA. 2001; 285: 2486-2497
        • Grundy S.M.
        • Cleeman J.I.
        • Mertz N.B.
        • Brewer H.B.
        • Clark L.T.
        • Hunninghake D.B.
        • Pasternak R.C.
        • Smith S.C.
        • Stone N.J.
        Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
        Circulation. 2004; 110: 227-239
      1. Physician’s Desk Reference 2004. 58th ed. Thomson PDR, Montvale, NJ2004: 644-647 (1055–1060, 2090–2097, 2178–2183, 2326–2331, 2585–2588.)
        • Jones P.H.
        • Davidson M.
        • Stein E.
        • Bays H.
        • McKenney J.
        • Miller E.
        • Cain V.
        • Blasetto J.
        • Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin (STELLAR) Study Group
        Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial).
        Am J Cardiol. 2003; 92: 152-160
        • Knapp H.H.
        • Schrott H.
        • Ma P.
        • Knopp R.
        • Chin B.
        • Gaziano J.M.
        • Donovan J.M.
        • Burke S.K.
        • Davidson M.H.
        Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia.
        Am J Med. 2001; 110: 352-360
        • Hunninghake D.
        • Insull W.
        • Toth P.
        • Davidson D.
        • Donovan J.M.
        • Burke S.K.
        Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively.
        Atherosclerosis. 2001; 158: 407-416
        • Davidson M.H.
        • McGarry T.
        • Bettis R.
        • Melani L.
        • Lipka L.J.
        • LeBeaut A.P.
        • Suresh R.
        • Sun S.
        • Veltri E.P.
        Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia.
        J Am Coll Cardiol. 2002; 40: 2125-2134
        • Ballantyne C.M.
        • Houri J.
        • Natarbartolo A.
        • Melani L.
        • Lipka L.J.
        • Suresh R.
        • Sun S.
        • LeBeaut A.P.
        • Sager P.T.
        • Veltri E.P.
        Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia.
        Circulation. 2003; 107: 2409-2415
        • Wolfe M.L.
        • Vartanian S.F.
        • Ross J.L.
        • Bansavich L.L.
        • Mohler E.R.
        • Meagher E.
        • Friedrich C.A.
        • Rader D.J.
        Safety and effectiveness of niaspan when added sequentially to a statin for treatment of dyslipidemia.
        Am J Cardiol. 2001; 87: 476-479
        • Brown B.G.
        • Bardsley J.
        • Poulin D.
        • Hillger L.A.
        • Dowdy A.
        • Maher V.M.G.
        • Zhao X.Q.
        • Albers J.J.
        • Knopp R.H.
        Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dL in patients with hyperlipidemia and coronary artery disease.
        Am J Cardiol. 1997; 80: 111-115
        • Bakker-Arkema R.G.
        • Nawrocki J.W.
        • Balck D.M.
        Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels.
        Atherosclerosis. 2000; 149: 123-129
        • Shepard J.
        • Cabarns I.
        • Harris S.
        • Caplan R.
        • Pears J.
        Safety of rosuvastatin in patients developing LDL-C <80 mg/dL and <50 mg/dL in clinical trials.
        Atheroscler Suppl. 2002; (Abstract 644.): 205
        • Wiviott S.D.
        • Morrow D.A.
        • Cairns R.
        • Pfeffer M.A.
        • Cannon C.P.
        • PROVE-IT TIMI 22 Investigators
        Can LDL be too low? A safety analysis of the intensive treatment arm of PROVE-IT TIMI 22. 2004 (Presented at the 2004 American Heart Association Scientific Session; November 8; New Orleans, LA. Abstract 2340.)